Avexitide acetate is a synthetic peptide commercialized by Eiger BioPharmaceuticals, with a leading Phase III program in Hyperinsulinemia. According to Globaldata, it is involved in 13 clinical trials, of which 10 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Avexitide acetate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Avexitide acetate is expected to reach an annual total of $100 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Avexitide acetate Overview
Avexitide acetate is under development for the treatment of bariatric surgery-induced hyperinsulinemic hypoglycemia, congenital hyperinsulinism and non-insulinoma pancreatogenous hypoglycemia syndrome. It is developed as a new liquid formulation and is administered through intravenous and subcutaneous routes. The therapeutic candidate is a 31 amino acid peptide fragment of exenatide. It is a new chemical entity (NCE). It targets glucagon-like peptide 1 receptor.
Eiger BioPharmaceuticals Overview
Eiger BioPharmaceuticals (Eiger), formerly known as Celladon, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as Lonafarnib, Peginterferon lambda, avexitide, lonafarnib and ritonavir for hepatitis delta virus (HDV) infection, peginterferon lambda for hepatitis delta virus (HDV) infection, avexitide for post bariatric hypoglycemia (PBH), avexitide for congenital hyperinsulinism (HI) among others. The company also offers post-bariatric hypoglycemia prevention services. It also offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. Eiger is headquartered in Palo Alto, California, the US.
The company reported revenues of (US Dollars) US$15.8 million for the fiscal year ended December 2023 (FY2023), an increase of 17% over FY2022. The operating loss of the company was US$71.8 million in FY2023, compared to an operating loss of US$93.8 million in FY2022. The net loss of the company was US$75 million in FY2023, compared to a net loss of US$96.8 million in FY2022.
For a complete picture of Avexitide acetate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
